“Predictive Biomarkers, Sequencing, and Diagnostics, Oh My!” was moderated by Kristen Kluska and featured Dr. Tariq Kassum, CEO of Celsius Therapeutics, John Lubniewski, President & CEO of HTG Molecular Diagnostics, Ronnie Andrews, President & CEO of Oncocyte Corporation, and Dr. Katrik Krishnan, CMO of OncoNano Medicine, Inc.

• Celsius has a platform called SCOPE: Single-Cell Observations for Precision Effect, which supports a pipeline focusing on autoimmune and oncology indications.

• HTG discussed its efforts in precision medicine, including its ~20,000 gene transcriptome product and recent pivot to include therapeutics.

• OncoCyte highlighted it’s Determa platforms which could play a role in helping with treatment decisions and patient monitoring.

• OncoNano Medicine walked through its ON-BOARD (delivery of payloads to target) and OMNI (polyvalent STING activation) technologies.

#Cantorconferenceseries #Oncology #Hematology #Hemeonc #Cantorfitzgerald #Cantorhealthcare